422 related articles for article (PubMed ID: 11557479)
1. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
[TBL] [Abstract][Full Text] [Related]
2. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
[TBL] [Abstract][Full Text] [Related]
3. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Gumbo T; Drusano GL; Liu W; Ma L; Deziel MR; Drusano MF; Louie A
Antimicrob Agents Chemother; 2006 Nov; 50(11):3695-700. PubMed ID: 16954319
[TBL] [Abstract][Full Text] [Related]
4. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223
[TBL] [Abstract][Full Text] [Related]
5. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
Petraitiene R; Petraitis V; Groll AH; Candelario M; Sein T; Bell A; Lyman CA; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2148-55. PubMed ID: 10471556
[TBL] [Abstract][Full Text] [Related]
6. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.
Groll AH; Gullick BM; Petraitiene R; Petraitis V; Candelario M; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):596-600. PubMed ID: 11158761
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.
Andes D; Stamsted T; Conklin R
Antimicrob Agents Chemother; 2001 Mar; 45(3):922-6. PubMed ID: 11181381
[TBL] [Abstract][Full Text] [Related]
8. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
[TBL] [Abstract][Full Text] [Related]
9. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.
Dowell JA; Knebel W; Ludden T; Stogniew M; Krause D; Henkel T
J Clin Pharmacol; 2004 Jun; 44(6):590-8. PubMed ID: 15145966
[TBL] [Abstract][Full Text] [Related]
11. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Petraitis V; Petraitiene R; Groll AH; Sein T; Schaufele RL; Lyman CA; Francesconi A; Bacher J; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):471-9. PubMed ID: 11158743
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Kelaher AM; Sarafandi AA; Mickiene D; Groll AH; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2005 May; 49(5):2084-92. PubMed ID: 15855534
[TBL] [Abstract][Full Text] [Related]
13. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Gumbo T; Drusano GL; Liu W; Kulawy RW; Fregeau C; Hsu V; Louie A
Antimicrob Agents Chemother; 2007 Mar; 51(3):968-74. PubMed ID: 17194830
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.
Wiederhold NP; Kontoyiannis DP; Chi J; Prince RA; Tam VH; Lewis RE
J Infect Dis; 2004 Oct; 190(8):1464-71. PubMed ID: 15378439
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Andes D; Diekema DJ; Pfaller MA; Prince RA; Marchillo K; Ashbeck J; Hou J
Antimicrob Agents Chemother; 2008 Feb; 52(2):539-50. PubMed ID: 18070979
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Louie A; Deziel M; Liu W; Drusano MF; Gumbo T; Drusano GL
Antimicrob Agents Chemother; 2005 Dec; 49(12):5058-68. PubMed ID: 16304173
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Wiederhold NP; Tam VH; Chi J; Prince RA; Kontoyiannis DP; Lewis RE
Antimicrob Agents Chemother; 2006 Feb; 50(2):469-73. PubMed ID: 16436698
[TBL] [Abstract][Full Text] [Related]
19. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.
Groll AH; Wood L; Roden M; Mickiene D; Chiou CC; Townley E; Dad L; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2554-63. PubMed ID: 12121932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
